Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Trends Endocrinol Metab. 2020 Nov;31(11):859-871. doi: 10.1016/j.tem.2020.08.001. Epub 2020 Sep 3.
Melatonin has significant inhibitory effects in numerous cancers, especially breast cancer. In estrogen receptor (ER)-positive human breast cancer, the oncostatic actions of melatonin are mainly achieved by suppressing ER mRNA expression and ER transcriptional activity via the MT1 receptor. Melatonin also regulates the transactivation of nuclear receptors, estrogen-metabolizing enzymes, and the expression of related genes. Furthermore, melatonin suppresses tumor aerobic glycolysis, critical cell-signaling pathways relevant to cell proliferation, survival, metastasis, and overcomes drug resistance. Studies in animal and human models indicate that disruption of the circadian nocturnal melatonin signal promotes the growth, metabolism, and signaling of human breast cancer, resulting in resistance to hormone therapy and chemotherapy, which may be reversed by melatonin.
褪黑素对多种癌症具有显著的抑制作用，尤其是乳腺癌。在雌激素受体（ER）阳性的人乳腺癌中，褪黑素的肿瘤抑制作用主要通过 MT1 受体抑制 ERmRNA 表达和 ER 转录活性来实现。褪黑素还调节核受体、雌激素代谢酶的转激活以及相关基因的表达。此外，褪黑素抑制肿瘤有氧糖酵解、与细胞增殖、存活、转移相关的关键细胞信号通路，并克服耐药性。动物和人体模型的研究表明，昼夜节律性夜间褪黑素信号的破坏促进了人乳腺癌的生长、代谢和信号转导，导致对激素治疗和化疗的耐药性，而褪黑素可能逆转这种耐药性。
